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Results Background
• Lung adenocarcinoma (LUAD) is an aggressive form 
of non-small cell lung cancer1
• 30% of LUAD patients have mutations in the Kirsten 
rat sarcoma viral oncogene (K-ras)1
• K-ras mutations are challenging to directly treat due to 
drug resistance2
• Transcription factor STAT3 is a major component of 
tumor associated inflammation in K-ras mutant tumors3
• STAT3 upregulates immune checkpoint molecules PD-
1/PD-L14
• Targeting downstream or co-occurring pathways of K-
ras may provide new targeted therapy
Aim
We treated a K-ras mutant lung cancer mouse model, 
CC-LR, with TTI-101 (a STAT3 inhibitor) and/or anti-PD-1 
to investigate the significance of targeting 
downstream/co-occurring pathways of K-ras
Methodology
• CC-LR lung cancer mice were treated with TT1-101 
(provided by Tweardy and Eckols) and/or anti-PD-1 
from 10 to 14 weeks of age
• Lung samples were extracted and stained with 
Hematoxylin and Eosin (H&E) staining to determine 
tumor area percentage
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Figure 4. immune cell composition of different treatments in CC-LR mice. Figures produced by 
Michael J. Clowers
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Figure 1. K-ras induced lung cancer mouse model, CC-LR, breeding scheme.
Figure 2. Injection of TTI-101 reduces tumor number and area in CC-LR mice. Figures produced by 
Marco A. Ramos-Castaneda and Stephen Peng.
Figure 3. TTI-101 +/- anti-PD1 treatment trends toward reduced surface tumor number, but not 
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Conclusion
• Based on preliminary data, single treatment of TTI-101 
trends toward reduced tumor number
• Combination treatment of TTI-101 and anti-PD-1 
trends toward reduced tumor number and area.
• Combination treatment, when compared to single 
treatment, is not significant 
• Personalized treatment with TT1-101 and anti-PD-1 
may serve as an alternative approach in the future



































Figure 5. TTI-101 oral gavage causes modest weight loss in CC-LR mice. Figures produced by 
Michael J. Clowers and Cody Chou
Future Work
• We plan to perform immunohistochemistry staining to
detect pSTAT3
• We also plan to perform qPCR to detect inflammatory 
markers in the tumor environment
